Methods of quantifying methotrexate metabolites
View Patent ↗The present invention provides a method for efficiently converting methotrexate polyglutamates to methotrexate in a cellular extract by contacting the cellular extract with gamma glutamyl hydrolase under conditions suitable for efficient conversion of methotrexate polyglutamates to methotrexate.
1. A method for determining a level of methotrexate polyglutamates (MTXPGs) in a cellular lysate, comprising the steps of:
(a) converting said MTXPGs to methotrexate (MTX) in said cellular lysate with gamma glutamyl hydrolase under conditions suitable for efficient conversion of MTXPGs to MTX;
(b) determining said level of MTXPGs by UV irradiating and chromatographing said MTX under conditions effective to produce a fluorescent MTX photolytic product, having an excitation wavelength in the range of 250 nm to 290 nm, wherein the fluorescence excitation maxima of said photoproduct is 274 nm in water;
(c) detecting fluorescence at an emission wavelength in the range of 440 nm to 500 nm, wherein the fluorescence emission maxima of said photoproduct is 464 nm in water; and
(d) correlating the level of fluorescent MTX photolytic product with said level of MTXPGs in said cellular lysate by a standard curve.
2. The method of claim 1 , wherein step (a) comprises contacting said cellular lysate with plasma comprising gamma glutamyl hydrolase.
3. The method of claim 1 , wherein said cellular lysate is a fractionated cellular lysate based on the enrichment of MTX or polyglutamates thereof.
4. The method of claim 1 or claim 3 , wherein said cellular lysate is a red blood cell lysate.
5. The method of claim 1 or claim 3 , wherein said cellular lysate is a leukocyte lysate.
6. The method of claim 1 or claim 3 , wherein said cellular lysate is a human cellular lysate.
7. The method of claim 6 , wherein said cellular lysate is from an individual having an autoimmune disease.
8. The method of claim 7 , wherein said cellular lysate is from an individual having arthritis.
9. The method of claim 7 , wherein said cellular lysate is from an individual having a condition selected from the group consisting of rheumatoid arthritis, polyarthritis, systemic lupus erythematosus, and psoriasis.
10. The method of claim 6 , wherein said cellular lysate is from an individual having cancer.
11. The method of claim 1 , wherein said chromatographing comprises high performance liquid chromatography (HPLC).
12. The method of claim 1 , wherein step (b) comprises contacting said MTX with radiation having a wavelength in the range of 225 nm to 275 nm to produce said photolytic product.
13. The method of claim 1 , wherein step (c) comprises detecting fluorescence of said photolytic product at an excitation wavelength in the range of 260 nm to 280 nm.
14. The method of claim 1 , wherein step (c) further comprises detecting fluorescence of said photolytic product at an excitation wavelength in the range of 360 nm to 410 nm.
15. A method of optimizing therapeutic efficacy or reducing toxicity associated with methotrexate (MTX) therapy administered to an individual, comprising the steps of:
(a) converting methotrexate polyglutamates (MTXPGs) to MTX in a cellular lysate from said individual with gamma glutamyl hydrolase under conditions suitable for efficient conversion of MTXPGs to MTX;
(b) determining said level of MTXPGs by UV irradiating and chromatographing said MTX under conditions effective to produce a fluorescent MTX photolytic product, having an excitation wavelength in the range of 250 nm to 290 nm, wherein the fluorescence excitation maxima of said photoproduct is 274 nm in water;
(c) detecting fluorescence at an emission wavelength in the range of 440 nm to 500 nm, wherein the fluorescence emission maxima of said photoproduct is 464 nm in water;
(d) correlating said level of fluorescent MTX photolytic product with said level of MTXPGs in said cellular lysate by a standard curve; and
(e) selecting a drug or dosage that is based on the level of said correlated level of MTXPGs determined by step (d) for subsequent administration to said individual.
16. The method of claim 15 , wherein said cellular lysate is obtained from a target cell for MTX therapy.
17. The method of claim 15 , wherein said cellular lysate is obtained from a non-target cell for MTX therapy.
18. The method of claim 15 , comprising reducing the dose of MTX administered to said individual.
19. The method of claim 15 , comprising increasing the dose of MTX administered to said individual.
20. The method of claim 15 , wherein the drug is folic acid, or a derivative thereof.
21. The method of claim 1 , wherein said conditions of step (a) comprise a pH of at least 4.
22. The method of claim 21 , wherein said conditions of step (a) comprise a pH in the range of 6 to 7.
23. The method of claim 1 , wherein step (b) comprises irradiating said MTX for 0.5 to 60 seconds.
24. The method of claim 23 , wherein step (b) comprises irradiating said MTX for 0.5 to 15 seconds.
25. The method of claim 1 , wherein said chromatographing occurs prior to said UV irradiating.
26. The method of claim 1 , wherein step (b) comprises HPLC with an aqueous mobile phase having a pH of 2 to 8.
27. The method of claim 26 , wherein said aqueous mobile phase has a pH of 4 to 7.
28. The method of claim 26 , wherein said aqueous mobile phase has a pH of 6 to 7.
29. The method of claim 1 , wherein step (b) comprises HPLC with an aqueous mobile phase having at most 20% acetonitrile.
30. The method of claim 29 , wherein said aqueous mobile phase has at most 15% acetonitrile.
31. The method of claim 1 , wherein step (b) comprises HPLC with an aqueous mobile phase having 0.05% to 1% H 2 O 2 .
32. The method of claim 31 , wherein said aqueous mobile phase has 0.3% to 0.6% H 2 O 2 .